Deals
SoftBank-Led Funding Triples Asia Health Startup’s Valuation
- Sequoia, EDBI, Openspace, MassMutual Ventures also join round
- Biofourmis focuses on digital therapeutics and virtual care
This article is for subscribers only.
SoftBank Group Corp. led a $100 million investment in Biofourmis Pte, nearly tripling the valuation of a software startup that predicts problems for patients with heart conditions.
SoftBank’s financing came from the Vision Fund 2, a successor to the Japanese giant’s initial $100 billion fund. Existing backers EDBI of Singapore, MassMutual Ventures, Openspace Ventures and Sequoia Capital also joined the Series C round.